Atrial fibrillation, venous thromboembolism, and mechanical heart valve replacement are cardiovascular disorders that rely on anticoagulation medication. When it comes to oral anticoagulants, warfarin has been the gold standard for over 60 years due to its effectiveness in avoiding thrombotic events. The hunt for better alternatives has been motivated by its limited therapeutic window, many drug-drug interactions, and genetic heterogeneity in metabolism. One oral anticoagulant under research that aims to address these concerns is tecarfarin (ATI-5923). Tecarfarin, a novel vitamin K antagonist, provides a potential option that may improve safety and effectiveness, especially for individuals with complicated medical demands, according to its distinctive metabolic profile.
The most common vitamin K antagonist, warfarin, is a major competitor to tecarfarin. Although phenprocoumon and acenocoumarol are not as widely utilized in the US, they are in other places where they are effective vitamin K antagonists. Another group of drugs that compete are direct oral anticoagulants (DOACs), which include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa). Not all patients can use direct-acting anticoagulants (DOACs), especially those with mechanical heart valves or severe renal impairment; nonetheless, they are less monitored and directly block specific clotting factors than vitamin K antagonists. If tecarfarin can overcome warfarin's drawbacks while keeping the advantages of vitamin K antagonism, it will be in a league of its own.
Chemical Characteristics
Tecarfarin has a more complicated molecular structure than warfarin, with a molecular weight of 460.328 g/mol and a molecular formula of C21H14F6O5. The compound has a hexafluoroisopropanol moiety and a chromenone ring system, as shown by its IUPAC nomenclature (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate. Six fluorine atoms give it its distinctive metabolic profile and make it more stable.
|
Property
|
Details
|
|
Chemical Formula
|
C21H14F6O5
|
|
Molecular Weight
|
460.328 g/mol
|
|
IUPAC Name
|
(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
|
|
SMILES
|
CC(C(F)(F)F)(C(F)(F)F)OC(=O)c1ccc(cc1)Cc2c(c3ccccc3oc2=O)O
|
|
InChI
|
1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
|
|
InChI Key
|
QFLNTQDOVCLQKW-UHFFFAOYSA-N
|
The risk of drug-drug interactions is lower with tecarfarin than with warfarin because it is metabolized by carboxylesterases, especially human carboxylesterase 2 (CES2), instead of the cytochrome P450 system.
The Evolution of the Product
The original developers of tecarfarin were ARYx Therapeutics, Inc.; Armetheon, Inc. and Cadrenal Therapeutics, Inc. followed in their footsteps. Its effectiveness as a vitamin K antagonist was shown in preclinical research in the early 2000s, which prompted Phase I trials to evaluate the drug's safety, tolerability, and pharmacokinetics in both healthy individuals and those with chronic kidney disease (CKD). Comparing tecarfarin to warfarin in phase II and II/III studies revealed similar safety and effectiveness in people with atrial fibrillation and other indications. The Food and Drug Administration (FDA) designated tecarfarin an orphan drug, and recent efforts have focused on niche populations like patients with LVADs and end-stage kidney disease (ESKD) associated with atrial fibrillation.
Advantages to Health Tecarfarin's principal advantage to health is its capacity to cure and prevent blood clots, which in turn lowers the risk of thrombotic events such as strokes and heart attacks. This has great promise for those dealing with:
Patients with abnormal heart rhythms may benefit from atrial fibrillation as a means to avoid stroke.
To lessen the likelihood of thromboembolism, mechanical heart valves are used.
Patients with implanted cardiac devices may control their anticoagulation with the use of LVADs.
In cases with ESKD accompanied by atrial fibrillation, conventional anticoagulants may have less efficacy owing to renal impairment.
Patients who take numerous drugs or have genetic variants that impact warfarin metabolism may benefit from this medication since it is metabolized by carboxylesterases instead of cytochrome P450 enzymes, which predicts fewer drug interactions. According to clinical research, tecarfarin has the potential to improve anticoagulation stability by increasing the time in therapeutic range (TTR) in certain subgroups.
Possible Impacts
Although tecarfarin prevents blood clots from forming, it also raises the risk of bleeding, which may range from mild bruising to serious hemorrhage. Tecarfarin was shown to have the same anticoagulation quality and adverse effects as warfarin in a Phase II/III study including 607 participants (Wikipedia). Analysis of subgroups uncovered:
|
Patient Group
|
Tecarfarin TTR
|
Warfarin TTR
|
P-value
|
|
CYP2C9 Interacting Drugs
|
72.2% (n=92)
|
69.9% (n=87)
|
0.16
|
|
CYP2C9 Variant Allele + Interacting Drug
|
76.5% (n=24)
|
69.5% (n=31)
|
0.24
|
Even in patients with artificial heart valves, tecarfarin showed no signs of thrombotic or embolic events, indicating strong effectiveness. Nevertheless, vigilant observation is required due to the potential for bleeding.
To prevent the breakdown of vitamin K—an ingredient necessary for the production of clotting factors II, VII, IX, and X—tecarfarin blocks the enzyme vitamin K epoxide reductase (VKOR). Tecarfarin prevents blood clots from forming by lowering these variables. To reduce medication interactions, tecarfarin is metabolized by carboxylesterases rather than cytochrome P450 enzymes (CYP2C9 and CYP3A4), as is the case with warfarin (Wikipedia). With this metabolic route, individuals with CYP2C9 or VKORC1 genetic polymorphisms have more predictability and less variability.
Risk prevention
In eleven clinical studies with more than a thousand people, tecafarin was shown to be generally well-tolerated by both healthy adults and those with chronic kidney disease or end-stage renal disease (ESRD) (Cadrenal). The results of a Phase I study in patients with CKD Stage 4 showed that there was little effect from renal impairment (TCTMD), as seen by a <15% rise in plasma concentration and an 8% drop in half-life compared to healthy volunteers. Because it is not metabolized by CYP450, it is safer in polypharmacy situations than warfarin and may have fewer medication interactions.
Dangers and Safety Measures
Similar to warfarin, tecarfarin may cause bleeding, which can range from mild bruising to serious hemorrhage, and the particular adverse effects are not well described. When compared to warfarin, there was no discernible change in adverse effects reported in clinical studies (Wikipedia). Maintaining therapeutic levels (usually 2.0-3.0) requires patients to undergo frequent INR monitoring. Here are some precautions:
In order to stabilize INR, it is important to maintain dietary consistency and avoid changes in vitamin K-rich foods, such as leafy greens.
Minimizing activities that provide a risk of trauma or bleeding is an important part of injury prevention.
Warn patients using antiplatelet or nonsteroidal anti-inflammatory medications (NSAIDs) because of the potential for adverse medication reactions.
Dosage Guidelines
The half-life of tecarfarin is 87-136 hours, which allows for a once-daily oral administration (Wikipedia). Therapeutic anticoagulation was achieved in clinical studies with doses ranging from 10-40 mg daily, adjusted according to INR values. Although patient compliance is supported by the lengthy half-life, personalized dosage is necessary because of the diversity in response.
Situations involving active bleeding include hemorrhage inside the brain or the intestines.
Reason being: heightened risk of bleeding after recent major surgery.
A history of brain hemorrhage is a hallmark of hemorrhagic stroke.
Severe Hepatic Impairment: Because metabolic processes may be impacted by liver function.
Pregnancy: Because vitamin K antagonists may cause damage to the developing fetus.
The lack of precise data necessitates inferring these contraindications from the warfarin profile and the tecarfarin mechanism.
A Look at Clinical Trials
Eleven studies involving more than a thousand people have shown that tecarcarin is both safe and effective (Cadrenal). There were no thrombotic events in individuals treated with tecarfarin, according to a major Phase II/III study (n=607), which demonstrated anticoagulation that was equivalent to warfarin (Wikipedia). Its usage in chronic kidney disease (CKD) patients was backed by a Phase I study that verified its pharmacokinetic stability (TCTMD). The purpose of the current Phase III studies is to determine its function in LVAD patients (BioSpace).
